| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Departments of Medicine, Biokinesiology and Physical Therapy, and of Biometry, Keck School of Medicine of the University of Southern California, and the 2 Life Sciences Division, Lawrence Berkeley National Laboratory, Los Angeles, California 90033
Thirty human immunodeficiency virus
(HIV)-infected men were randomized to a high dose of nandrolone
decanoate weekly (group 1) or nandrolone plus resistance
training (group 2) for 12 wk. For the two groups, nandrolone
had no significant effects on total cholesterol, LDL cholesterol, LDL
phenotype, or fasting triglycerides, although triglycerides decreased
by 66 ± 124 mg/dl for the entire population (P = 0.01). Group 2 subjects had a favorable increase of 5.2 ± 7.7Å in LDL particle size (P = 0.03), whereas there
was no change in group 1. Lipoprotein(a) decreased by
7.3 ± 6.8 mg/dl for group 1 (P = 0.002) and by 6.9 ± 8.1 for group 2 (P = 0.013). However, HDL cholesterol decreased by 8.7 ± 7.4 mg/dl
for group 1 (P < 0.001) and by 10.6 ± 5.9 for group 2 (P < 0.001). Percentages of
HDL2b (9.7-12 nm) and HDL2a (8.8-9.7
nm) subfractions decreased similarly for the two groups, whereas
HDL3a (8.2-8.8 nm) and HDL3b (7.8-8.2
nm) increased in the groups during study therapy (P 
0.02 for all comparisons). There was no evidence of a decreased insulin
sensitivity in either group, whereas fasting glucose, fasting insulin,
and homeostasis model assessment improved in group 2 (P < 0.05). These metabolic effects were favorable
(other than for HDL), but changes were generally transient (except for HDL in group 2), with measurements returning to baseline 2 mo after the interventions were completed.
anabolic steroids; lipoprotein(a); androgen therapy; insulin resistance; high-density lipoprotein cholesterol; low-density lipoprotein cholesterol; serum triglycerides
This article has been cited by other articles:
|
|
 |
|
  K. Mulligan, R. Zackin, R. A. Clark, B. Alston-Smith, T. Liu, F. R. Sattler, T. B. Delvers, J. S. Currier, and for the AIDS Clinical Trials Group 329 Study Team Effect of Nandrolone Decanoate Therapy on Weight and Lean Body Mass in HIV-Infected Women With Weight Loss: A Randomized, Double-blind, Placebo-Controlled, Multicenter Trial Arch Intern Med, March 14, 2005; 165(5): 578 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J Batterham Investigating heterogeneity in studies of resting energy expenditure in persons with HIV/AIDS: a meta-analysis Am. J. Clinical Nutrition, March 1, 2005; 81(3): 702 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cuerda, A. Zugasti, I. Breton, M. Camblor, P. Miralles, and P. Garcia Treatment With Nandrolone Decanoate and Megestrol Acetate in HIV-Infected Men Nutr Clin Pract, February 1, 2005; 20(1): 93 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. T. Schroeder, L. Zheng, K. E. Yarasheski, D. Qian, Y. Stewart, C. Flores, C. Martinez, M. Terk, and F. R. Sattler Treatment with oxandrolone and the durability of effects in older men J Appl Physiol, March 1, 2004; 96(3): 1055 - 1062. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. A. Evans Current Concepts in Anabolic-Androgenic Steroids Am. J. Sports Med., March 1, 2004; 32(2): 534 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. T. Schroeder, M. Terk, and F. R. Sattler Androgen therapy improves muscle mass and strength but not muscle quality: results from two studies Am J Physiol Endocrinol Metab, July 1, 2003; 285(1): E16 - E24. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
